Lipo-B (B12 + MIC): What It Is, Where to Get It Prescribed, and What It Costs

Lipo-B is not a peptide, a hormone or a signalling molecule. It is a sterile injectable solution of four ordinary nutrients that the body already handles every day through food: the amino acid methionine, the sugar-alcohol inositol, the essential nutrient choline, and vitamin B12. The "50mg/50mg/25mg/1mg/mL" on the label is the concentration of each per millilitre, in that order: 50 mg methionine, 50 mg inositol, 25 mg choline and 1 mg vitamin B12 in every millilitre, in a 10 mL multi-dose vial.

The B12 in Lipo-B is cyanocobalamin, the standard pharmaceutical form of the vitamin and the form used in FDA-approved B12 injections. It is converted in the body to the two active coenzyme forms, methylcobalamin and adenosylcobalamin. Pepti supplies the active methylcobalamin form on its own as a separate product, Methylcobalamin; the distinction is covered in the comparison section further down.

Because the ingredients are nutrients rather than drugs in the usual sense, the useful question is not "what does Lipo-B do?" but "what does each ingredient do, at this dose, given by this route?" Those are four different answers with four different levels of evidence, and the rest of this page keeps them separate.

MIC is simply the initials of methionine, inositol and choline. "Lipotropic" is an older nutrition term for substances that, in animal feeding studies from the middle of the twentieth century, were described as preventing fat from accumulating in the liver of animals fed a choline-deficient diet. Choline was the original lipotrope; methionine was grouped with it because it can donate the methyl groups the liver uses to make its own choline; inositol was added because it is a component of the phospholipids that package fat for export from the liver. A 2013 survey in Critical Reviews in Food Science and Nutrition uses the same definition, framing lipotropes as dietary compounds involved in hepatic lipid metabolism rather than as agents that act on body fat generally.

That history matters because "lipotropic" is routinely misread as "fat-burning". The original meaning is narrower and more specific: it describes liver lipid handling in deficient animals, not fat loss in people who are eating a normal diet.

Lipo-B is not a weight-loss medication, and it is not described as one in the published literature. It does not act on appetite hormones, it does not change how much you absorb, and it is not in the same category as the GLP-1 receptor agonists that have randomised human trial evidence for weight management. It is not a stimulant, and it is not an energy drug in the sense of caffeine; whatever change in energy people report from B12 is tied to whether they were low in B12 to begin with. It is not a liver treatment for a diagnosed liver condition, which is a physician's question and is not what a compounded nutrient injection is for. And it is not a substitute for the diet and activity programme it is usually prescribed alongside.

Cyanocobalamin is converted to methylcobalamin, which is the cofactor for methionine synthase, the enzyme that regenerates methionine from homocysteine and in doing so keeps the folate cycle turning. The other active form, adenosylcobalamin, is the cofactor for methylmalonyl-CoA mutase in mitochondria. When B12 is short, homocysteine and methylmalonic acid accumulate, DNA synthesis in rapidly dividing cells slows (which is why deficiency shows up as large red blood cells), and myelin maintenance suffers (which is why it also shows up as numbness, tingling and cognitive change). This is textbook human physiology, described in the New England Journal of Medicine's 2013 clinical practice review and in the 2017 Nature Reviews Disease Primers article on B12 deficiency.

The important corollary is that these are deficiency mechanisms. Once the enzymes have the cofactor they need, giving more cofactor does not make them run faster.

Choline is needed to make phosphatidylcholine, the phospholipid that coats very-low-density lipoprotein particles. Without enough of it the liver cannot package triglyceride for export, and fat accumulates in liver cells. This is the mechanism behind the original "lipotropic" observation in animals, and it has been reproduced in humans: controlled feeding studies in which adults were deliberately deprived of choline produced fatty liver and liver-enzyme changes that reversed when choline was restored, as reviewed in Advances in Nutrition in 2016 and in Nutrition Reviews in 2009. Choline is also the precursor of acetylcholine and a methyl donor via betaine.

The scale is worth stating plainly. The adequate intake for choline set by the US Institute of Medicine is 550 mg a day for adult men and 425 mg for adult women, and it comes from eggs, meat, fish, dairy and legumes. A 0.8 mL dose of Lipo-B contains 20 mg of choline. The injection is not a meaningful contribution to choline status in anyone eating a mixed diet.

Methionine is one of the nine essential amino acids and the direct precursor of S-adenosylmethionine, the body's main methyl donor. In the lipotrope story it is included because methyl groups from methionine allow the liver to synthesise phosphatidylcholine by a second route, partially sparing dietary choline. A 0.8 mL dose supplies 40 mg of methionine. A single egg contains roughly ten times that, and a normal diet supplies on the order of a gram or more a day. No published human study describes a metabolic effect from methionine at the amount delivered by a lipotropic injection.

Myo-inositol is a component of the phosphatidylinositol phospholipids and the precursor of inositol phosphate second messengers, including those downstream of the insulin receptor. That is the basis for its study in insulin-resistance conditions, and there are randomised human trials of oral myo-inositol in polycystic ovary syndrome, summarised in a 2023 meta-analysis in Reproductive Biology and Endocrinology. Those trials used oral doses in the range of 2 to 4 grams a day. A 0.8 mL dose of Lipo-B contains 40 mg, roughly one-fiftieth to one-hundredth of that, so the PCOS literature does not transfer to this product and should not be read as though it does.

This is the one ingredient with an established, guideline-level indication. B12 deficiency is common, particularly in older adults, in people taking metformin or acid-suppressing medication, in people who have had gastric or bariatric surgery, in pernicious anaemia and in vegetarians and vegans. Treatment with B12 corrects the anaemia, the elevated methylmalonic acid and homocysteine, and, if caught early enough, the neurological symptoms. The 2013 New England Journal of Medicine review and the 2017 Nature Reviews Disease Primers article both lay this out, and cyanocobalamin injection is an FDA-approved drug for exactly this purpose.

Intramuscular injection has traditionally been used because it bypasses the intrinsic-factor absorption step that is broken in pernicious anaemia. A 2018 Cochrane review comparing oral with intramuscular B12 for deficiency found that high-dose oral B12 appeared to normalise serum levels about as well as injections in the trials available, while grading the evidence as low quality. The practical reading is that injection is a legitimate route, not a uniquely necessary one for most people, and the choice between them is a physician's call.

Here the evidence points the other way, and it is worth being direct about it. The current page's original summary said it in one line: benefit in people with normal levels is limited. A 2018 randomised, double-blind, placebo-controlled trial in Clinical Nutrition ESPEN gave supplementary B12 to patients with irritable bowel syndrome or inflammatory bowel disease who were not deficient and found no reduction in fatigue compared with placebo. That is the pattern across the field: B12 relieves fatigue when fatigue is a symptom of deficiency, and does not when it is not. Nobody has shown that pushing an already-normal B12 level higher does anything, by mouth or by injection.

The human data on choline is about deficiency and adequacy, not supplementation on top of a normal diet. Depletion studies show that removing choline causes fatty liver in adults and that restoring it reverses the change. Observational work, including a 2012 cohort study in the American Journal of Clinical Nutrition, reports that lower dietary choline intake is associated with more severe liver fat in patients with non-alcoholic fatty liver disease. None of this work involved injected choline, and none of it used amounts anywhere near as small as 20 mg per dose.

For inositol the human trial evidence is oral, gram-scale and in PCOS, as above. For methionine there is no human trial evidence of any benefit from supplementation in people eating a normal diet; if anything the animal literature runs the other way, with methionine restriction rather than supplementation being the direction of interest in metabolic research. Neither has been tested as an injected 40 mg dose.

There are no randomised human trials of the methionine, inositol and choline combination given as an injection, with or without B12, for weight, body composition, energy or liver fat. A PubMed search for the combination returns no controlled trials at all; what exists is the animal nutrition work behind the word "lipotropic", the deficiency literature on each nutrient individually, and decades of clinical use in weight-management clinics without a trial to anchor it.

The honest framing is therefore split. For the B12 component: established human evidence for deficiency, with FDA-approved single-ingredient products, and human trial evidence that it does not help fatigue in people who are replete. For the MIC component: plausible biochemistry, deficiency data in animals and in controlled human depletion studies, and no evidence that the small injected amounts change anything in a nourished adult. A source that tells you the MIC part "burns fat" or "boosts metabolism" is not describing the research.

• It does not establish that Lipo-B produces weight loss or fat loss. No trial has tested it, and no outcome claim on that point is supportable.
• It does not establish that the MIC ingredients, at these doses and by this route, have any measurable effect in people eating a normal diet.
• It does not establish that injected B12 improves energy in someone whose B12 is already normal; the controlled trial evidence says it does not.
• It does not establish an effect on liver fat from the injection; the choline-and-liver literature is about dietary adequacy, not injections.
• It does not establish efficacy for any condition as an FDA-approved product. Lipo-B as a compounded combination is not approved for anything; only single-ingredient cyanocobalamin injection is.

A state-licensed 503A pharmacy may compound with a bulk substance if it meets one of three tests set by the Food, Drug, and Cosmetic Act: the substance complies with an applicable USP or NF monograph; or, if no monograph exists, it is a component of an FDA-approved drug product; or, if neither applies, it appears on the FDA's 503A bulks list. Substances nominated for that list but not yet decided are sorted into three interim categories, and the FDA has said it does not intend to act against compounding with Category 1 substances while its evaluation continues.

Cyanocobalamin (vitamin B12) is an approved drug in its own right. Drugs@FDA lists cyanocobalamin injection 1 mg/mL under active approved applications, so it clears the approved-drug-component route without needing to be on any list. It does not appear on any of the 503A nominated-substance categories, which is what you would expect.

Choline chloride, the salt used in MIC preparations, is in Category 1, "bulk drug substances under evaluation", on the FDA's 503A categories document updated 14 May 2026. Category 1 is the interim status under which compounding is permitted while the FDA evaluates the nomination; it is not the Category 2 "significant safety risk" list. A different salt, choline bitartrate, sits in Category 3 (nominated without adequate support), which is one reason the exact salt on a pharmacy's formulation record matters.

Methionine and inositol do not appear in any of the three categories on the 14 May 2026 document. Both are long-standing compendial substances with USP–NF monographs, which is the first of the three routes above and removes the need for nomination. The only inositol entry on the categories document is "inositol hexanicotinate", a different compound (a niacin ester) in Category 3, and it is not what is in Lipo-B.

Methylcobalamin, for completeness, is also in Category 1 on the same document. That is relevant to Pepti's separate Methylcobalamin product rather than to Lipo-B, whose B12 is cyanocobalamin.

Every ingredient in Lipo-B has a clear compounding pathway: an approved drug, a Category 1 substance, and two compendial nutrients. Nothing in it is flagged for safety concern. But the compounded combination itself is not an FDA-approved product and never will be in this form; compounded medications are prepared to a prescription by a licensed pharmacy, not approved as manufactured drugs. Only the single-ingredient cyanocobalamin injection is approved, and only for B12 deficiency. See are peptides FDA approved for how that distinction works generally.

If your B12 was low, this is where a change is plausible: less tiredness, and in people with deficiency-related tingling or numbness, the beginning of improvement. Serum B12 rises within days of an intramuscular dose. If your B12 was normal, the controlled trial evidence says you should not expect a change in energy, and reports of feeling different in the first week are more likely to be the effect of starting a structured programme than of the vitamin.

This is the period the injection is normally prescribed across as an adjunct to a diet and activity plan. Any change in weight over this window is the plan's, not the injection's; there is no trial evidence attributing weight change to Lipo-B, and prescribers who use it describe it as support alongside a programme rather than as the thing doing the work. The pharmacy's product page and your physician will both put it the same way.

Lipo-B is prescribed as an ongoing adjunct rather than as a time-limited course. Refills follow the 28-day cycle, and your physician decides whether continuing makes sense based on how the programme is going and, if a B12 level was checked, on what it shows.

If your fatigue did not change in the first month and your B12 was normal, the vitamin is not the answer to it, and the honest move is to look elsewhere with your physician rather than to keep injecting it. That is also the moment to ask whether a blood panel would clarify the picture.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.8 mL is 80 units on a U-100 syringe. You are not calculating anything; the number is printed on your medication. For the curious, that volume contains 40 mg methionine, 40 mg inositol, 20 mg choline and 0.8 mg of B12, which is arithmetic from the label rather than a separate dose.

Unlike most products on this site, Lipo-B is given into muscle rather than under the skin. Intramuscular is the traditional route for B12 injections and the one the pharmacy's directions specify. The usual sites are the outer upper thigh or the upper outer buttock, rotated between doses. Your directions and your physician will tell you which, and the pharmacy supplies syringes appropriate to the route. Do not switch to subcutaneous on your own; ask.

Twelve doses of 0.8 mL come out of a 10 mL vial (9.6 mL, with a little left for draw losses). At three injections a week, twelve doses is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always; a multi-dose vial has a beyond-use date once punctured and is not something to stockpile.

Lipo-B ships refrigerated in insulated packaging with ice packs, and it should stay refrigerated. B12 is light-sensitive, so the vial should also stay in its carton or out of direct light. The beyond-use date runs from first puncture and is on the label; a vial that has been out of the fridge for an extended period, or that has changed colour or gone cloudy, should not be used, and the pharmacy can tell you how to handle that.

Both deliver vitamin B12 by injection. Methylcobalamin is the active coenzyme form, given on its own; Lipo-B uses cyanocobalamin, which the body converts, and adds the three lipotropic nutrients. For treating or preventing B12 deficiency the two forms are broadly interchangeable in practice, and the choice between them is more about form preference and cost than about evidence. If B12 is the whole reason for the injection, the single-ingredient product is the simpler choice.

These are sibling lipotropic preparations from the same pharmacy family. Lipo-Mino-Mix-C is the MIC base built around a different accompanying profile, and its page carries its own composition. Neither has trial evidence for weight; both are prescribed as adjuncts. Which one, if either, is your physician's call.

L-Carnitine is a different molecule with a different literature: it is involved in transporting fatty acids into mitochondria and has been studied in randomised human trials, unlike the MIC combination. It is sometimes prescribed alongside a lipotropic injection and sometimes instead of one. They are not doing the same job.

Lipo-B is a vial and syringe product. It is not made as a pepti Pen cartridge, because the Pen is built around subcutaneous peptide dosing and Lipo-B is an intramuscular vitamin injection.